Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five patients with generalized myasthenia gravis (gMG) enrolled in a Phase 1b/2a clinical trial.
“I am very encouraged by the interim analysis findings,” as the therapy “appears safe and well tolerated, and the extent of clinical improvement seen in our early participants is remarkable,” Volkan Granit, MD, the trial’s principal investigator at the University of Miami, said in a press release.
Image: https://myastheniagravisnews.com
{iframe}https://myastheniagravisnews.com/news-posts/2022/05/17/car-t-cell-therapy-continues-show-promise-myasthenia-gravis/{/iframe}